A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
NCT03464097
Recruiting
This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/29/2023
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Crohn Disease
Register for Updates
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738
Recruiting
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire
Conditions: Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Register for Updates
Pulse-Width Modulation
NCT06120231
Recruiting
The overarching aim of this project is to modulate the pulse-width during stimulation of pedicle screws and record the response thresholds associated with each PWM setting. During this initial phase of the investigation, no further data will be collected.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Dartmouth-Health, Lebanon, New Hampshire
Conditions: Spinal Fusion, Spinal Stenosis
Register for Updates
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)
NCT05767034
Recruiting
The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) for 52 weeks in combination with prednisone tapered over 24 weeks in adult participants with PMR who have recently relapsed.
Gender:
All
Ages:
50 years and above
Trial Updated:
11/28/2023
Locations: Novartis Investigative Site, Lebanon, New Hampshire
Conditions: Polymyalgia Rheumatica
Register for Updates
SFDI in High Energy Lower Extremity Fracture
NCT05635617
Recruiting
This is a non-randomized prospective study of 20 patients with high energy lower extremity fractures evaluating feasibility and acceptability of SFDI, a real-time optical imaging technology.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Trauma Injury
Register for Updates
Rural New England Health Study (Phase 2)
NCT05466331
Recruiting
This study will integrate mobile hepatitis C virus (HCV) testing and treatment with expanded syringe access in order to improve uptake of HCV testing and treatment, and reduce syringe sharing behavior in rural northern New England. The intervention aims to reach rural opioid injectors with HCV and to fill service gaps identified around access to syringe services and HCV testing and treatment, while limiting the burden on local partners. If effective, this mobile model of HCV telehealth integrate... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Mobile Study Van, Keene, New Hampshire
Conditions: Hepatitis C, Opioid Use Disorder, IV Drug Usage
Register for Updates
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
NCT05321082
Recruiting
This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic Pulmonary Fibrosis (IPF) can join the study. If they already take nintedanib, they can continue treatment throughout the study. The purpose of this study is to find out whether a medicine called BI 1015550 helps people with PF-ILD. Participants are put into 3 groups randomly, which means by chance. Participants in 2 groups take different doses of B... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Lung Diseases, Interstitial
Register for Updates
A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (BALLAD)
NCT05267600
Recruiting
ARGX-113-2009 is an operationally seamless 2-part, phase 2/3, prospective, global, multicenter, randomized, double-blinded, placebo-controlled study to investigate the efficacy, safety, tolerability, immunogenicity, participant-reported outcome measures (including those assessing participant QoL), PK, and PD of efgartigimod PH20 SC administered via subcutaneous (SC) injection in adult participants with moderate to severe BP. This study intends to demonstrate that efgartigimod is an effective and... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Investigator site 85 - US0010159, Lebanon, New Hampshire
Conditions: Bullous Pemphigoid
Register for Updates
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
NCT04930094
Recruiting
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)
Gender:
All
Ages:
50 years and above
Trial Updated:
11/28/2023
Locations: Novartis Investigative Site, Lebanon, New Hampshire
Conditions: Giant Cell Arteritis (GCA)
Register for Updates
A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
NCT04302025
Recruiting
This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Non-small Cell Lung Cancer
Register for Updates
MANTIS Endoscopic Clipping Study
NCT05653843
Recruiting
This study is intended to document clinical effectiveness and safety pertaining to use of a new endoscopic clipping device MANTIS™ when used for hemostasis, closure, anchoring and marking.
Gender:
All
Ages:
All
Trial Updated:
11/27/2023
Locations: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Hemostasis, Perforation Colon, Feeding Tube Complication, Endoscopy
Register for Updates
Fiber-rich Foods, Weight Status, and the Gut Microbiota in NH Hispanic Adults at Risk for Food Insecurity
NCT05488912
Recruiting
This study will include a group of 60 Hispanic adults living in New Hampshire with or without overweight/obesity. The study aims to assess food access and intake of fiber-rich foods, characterize fecal microbiota composition, and assess the relationship between the intake of fiber-rich foods and components of the gut microbiota-gut-brain axis. These aims will be accomplished through biospecimen collection including a pre-collected stool sample, a fasting blood sample, and a Mixed Meal Tolerance... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
11/27/2023
Locations: University of New Hampshire Health & Wellness, Durham, New Hampshire
Conditions: Food Insecurity, Overweight and Obesity
Register for Updates